Associations of Serum Clara Cell Protein 16 with Severity and Prognosis in Adults with Community-Acquired Pneumonia

References

• Yu Y, Fei A. Atypical pathogen infection in community-acquired pneumonia. Biosci Trends. 2016;10(1):7–13. doi:10.5582/bst.2016.01021
   PubMed Web of Science ®Google Scholar
• Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163(7):1730–1754. doi:10.1164/ajrccm.163.7.at1010
   PubMed Web of Science ®Google Scholar
• Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175(10):1086–1093. doi:10.1164/rccm.200603-350OC
   PubMed Web of Science ®Google Scholar
• File TJ, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130–141. doi:10.3810/pgm.2010.03.2130
   PubMed Web of Science ®Google Scholar
• Mandell LA. Community-acquired pneumonia: an overview. Postgrad Med. 2015;127(6):607–615. doi:10.1080/00325481.2015.1074030
   PubMed Web of Science ®Google Scholar
• Le Roux DM, Zar HJ. Community-acquired pneumonia in children - a changing spectrum of disease. Pediatr Radiol. 2017;47(11):1392–1398. doi:10.1007/s00247-017-3827-8
   PubMed Web of Science ®Google Scholar
• Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis. 2011;52(Suppl 4):S296–S304. doi:10.1093/cid/cir045
   PubMed Web of Science ®Google Scholar
• Karakioulaki M, Stolz D. Biomarkers in pneumonia-beyond procalcitonin. Int J Mol Sci. 2019;20(8):2004. doi:10.3390/ijms20082004
   PubMed Web of Science ®Google Scholar
• Gu M, Han X, Liu X, Sui F, Zhang Q, Pan S. Predictive value of annexin A1 for disease severity and prognosis in patients with community-acquired pneumonia. Diagnostics. 2023;13(3):396. doi:10.3390/diagnostics13030396
   Web of Science ®Google Scholar
• Cerda-Mancillas MC, Santiago-Germán D, Andrade-Bravo B, et al. D-dimer as A biomarker of severity and adverse outcomes in patients with community acquired pneumonia. Arch Med Res. 2020;51(5):429–435. doi:10.1016/j.arcmed.2020.04.014
   PubMed Web of Science ®Google Scholar
• Li Q, Wu T, Li S. MiR-181b serves as diagnosis and prognosis biomarker in severe community-acquired pneumonia. Genet Mol Biol. 2021;44(3):e20200431. doi:10.1590/1678-4685-GMB-2020-0431
   PubMed Web of Science ®Google Scholar
• Liu H-Y, Xiang H-X, Xiang Y, et al. The associations of serum S100A9 with the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. BMC Infect Dis. 2021;21(1):327. doi:10.1186/s12879-021-06020-y
   PubMed Web of Science ®Google Scholar
• Cheng J-Y, Tang M-M, Fang P, et al. Longitudinal associations of serum survivin with the severity and prognosis of community-acquired pneumonia patients. Respir Investig. 2023;61(1):84–94. doi:10.1016/j.resinv.2022.09.007
   PubMed Web of Science ®Google Scholar
• Xu Z, Wang X-M, Cao P, et al. Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. Int J Med Sci. 2022;19(1):74–81. doi:10.7150/ijms.67028
   PubMed Web of Science ®Google Scholar
• Broeckaert F, Clippe A, Knoops B, Hermans C, Bernard A. Clara cell secretory protein (CC16): features as a peripheral lung biomarker. Ann N Y Acad Sci. 2000;923:68–77. doi:10.1111/j.1749-6632.2000.tb05520.x
   PubMed Web of Science ®Google Scholar
• Broeckaert F, Bernard A. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clin Exp Allergy. 2000;30(4):469–475. doi:10.1046/j.1365-2222.2000.00760.x
   PubMed Web of Science ®Google Scholar
• Manning CM, Johnston CJ, Hernady E, et al. Exacerbation of lung radiation injury by viral infection: the role of Clara cells and Clara cell secretory protein. Radiat Res. 2013;179(6):617–629. doi:10.1667/RR3279.1
   PubMed Web of Science ®Google Scholar
• Mukherjee AB, Zhang Z, Chilton BS. Uteroglobin: a steroid-inducible immunomodulatory protein that founded the Secretoglobin superfamily. Endocr Rev. 2007;28(7):707–725. doi:10.1210/er.2007-0018
   PubMed Web of Science ®Google Scholar
• Lakind JS, Holgate ST, Ownby DR, et al. A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects. Biomarkers. 2007;12(5):445–467. doi:10.1080/13547500701359327
   PubMed Web of Science ®Google Scholar
• Briana DD, Gourgiotis D, Boutsikou M, et al. Clara cell protein in full-term pregnancies: the influence of intrauterine growth restriction. Pediatr Pulmonol. 2010;45(12):1186–1191. doi:10.1002/ppul.21305
   PubMed Web of Science ®Google Scholar
• Rong B, Fu T, Gao W, et al. Reduced serum concentration of CC16 is associated with severity of chronic obstructive pulmonary disease and contributes to the diagnosis and assessment of the disease. Int J Chron Obstruct Pulmon Dis. 2020;15:461–470. doi:10.2147/COPD.S230323
   PubMed Web of Science ®Google Scholar
• Kropski JA, Fremont RD, Calfee CS, Ware LB. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest. 2009;135(6):1440–1447. doi:10.1378/chest.08-2465
   PubMed Web of Science ®Google Scholar
• Zhang S, Jia Q, Song J, et al. Clinical significance of CC16 and IL-12 in bronchoalveolar lavage fluid of various stages of silicosis. Ann Palliat Med. 2020;9(6):3848–3856. doi:10.21037/apm-20-1838
   PubMed Web of Science ®Google Scholar
• Laucho-Contreras ME, Polverino F, Tesfaigzi Y, Pilon A, Celli BR, Owen CA. Club cell protein 16 (CC16) augmentation: a potential disease-modifying approach for Chronic Obstructive Pulmonary Disease (COPD). Expert Opin Ther Targets. 2016;20(7):869–883. doi:10.1517/14728222.2016.1139084
   PubMed Web of Science ®Google Scholar
• Tsoumakidou M, Bouloukaki I, Thimaki K, Tzanakis N, Siafakas NM. Innate immunity proteins in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Exp Lung Res. 2010;36(6):373–380. doi:10.3109/01902141003690389
   PubMed Web of Science ®Google Scholar
• Janssen R, Sato H, Grutters JC, et al. Study of Clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis. Chest. 2003;124(6):2119–2125. doi:10.1378/chest.124.6.2119
   PubMed Web of Science ®Google Scholar
• Martin AC, Laing IA, Khoo SK, et al. Acute asthma in children: relationships among CD14 and CC16 genotypes, plasma levels, and severity. Am J Respir Crit Care Med. 2006;173(6):617–622. doi:10.1164/rccm.200509-1367OC
   PubMed Web of Science ®Google Scholar
• Lam DC, Kwok HH, Yu WC, et al. CC16 levels correlate with cigarette smoke exposure in bronchial epithelial cells and with lung function decline in smokers. BMC Pulm Med. 2018;18(1):47. doi:10.1186/s12890-018-0607-7
   PubMedGoogle Scholar
• Chakrabarti A, Nguyen A, Newhams MM, et al. Surfactant protein D is a biomarker of influenza-related pediatric lung injury. Pediatr Pulmonol. 2022;57(2):519–528. doi:10.1002/ppul.25776
   PubMed Web of Science ®Google Scholar
• Iannuzo N, Dy ABC, Guerra S, Langlais PR, Ledford JG. The impact of CC16 on pulmonary epithelial-driven host responses during mycoplasma pneumoniae infection in mouse tracheal epithelial cells. Cells. 2023;12(15):1984. doi:10.3390/cells12151984
   PubMed Web of Science ®Google Scholar
• Feng CM, Cheng JY, Xu Z, et al. Associations of serum resistin with the severity and prognosis in patients with community-acquired pneumonia. Front Immunol. 2021;12:703515. doi:10.3389/fimmu.2021.703515
   PubMed Web of Science ®Google Scholar
• Cao B, Huang Y, She DY, et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 Clinical Practice Guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J. 2018;12:1320–1360. doi:10.1111/crj.12674
   PubMed Web of Science ®Google Scholar
• Cao LF, Cheng JY, Xu Z, et al. Serum 8-Hydroxydeoxyguanosine is a potential indicator for the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. J Immunol. 2022;208(2):321–327. doi:10.4049/jimmunol.2100711
   PubMed Web of Science ®Google Scholar
• Jiang X, Huang CM, Feng CM, Xu Z, Fu L, Wang XM. Associations of serum S100A12 with severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. Front Immunol. 2021;12:714026. doi:10.3389/fimmu.2021.714026
   PubMed Web of Science ®Google Scholar
• Marti C, Garin N, Grosgurin O, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012;16(4):R141. doi:10.1186/cc11447
   PubMed Web of Science ®Google Scholar
• Kollef KE, Reichley RM, Micek ST, Kollef MH. The modified APACHE II score outperforms Curb65 pneumonia severity score as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chest. 2008;133(2):363–369. doi:10.1378/chest.07-1825
   PubMed Web of Science ®Google Scholar
• Feng CM, Wang XM, Li MD, et al. Serum interleukin-17 predicts severity and prognosis in patients with community acquired pneumonia: a prospective cohort study. BMC Pulm Med. 2021;21(1):393. doi:10.1186/s12890-021-01770-6
   PubMed Web of Science ®Google Scholar
• Zheng L, Fei J, Feng CM, Xu Z, Fu L, Zhao H. Serum 8-iso-PGF2α predicts the severity and prognosis in patients with community-acquired pneumonia: a retrospective cohort study. Front Med. 2021;8:633442. doi:10.3389/fmed.2021.633442
   Web of Science ®Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–e67. doi:10.1164/rccm.201908-1581ST
   PubMed Web of Science ®Google Scholar
• Fu L, Zhao H, Xiang Y, et al. Reactive oxygen species-evoked endoplasmic reticulum stress mediates 1-nitropyrene-induced epithelial-mesenchymal transition and pulmonary fibrosis. Environ Pollut. 2021;283:117134. doi:10.1016/j.envpol.2021.117134
   PubMed Web of Science ®Google Scholar
• Zheng L, Jiang YL, Fei J, et al. Circulatory cadmium positively correlates with epithelial-mesenchymal transition in patients with chronic obstructive pulmonary disease. Ecotoxicol Environ Saf. 2021;215:112164. doi:10.1016/j.ecoenv.2021.112164
   PubMed Web of Science ®Google Scholar
• Jiang YL, Fei J, Cao P, et al. Serum cadmium positively correlates with inflammatory cytokines in patients with chronic obstructive pulmonary disease. Environ Toxicol. 2022;37(1):151–160. doi:10.1002/tox.23386
   PubMed Web of Science ®Google Scholar
• Fei J, Fu L, Cao W, Hu B, Zhao H, Li JB. Low vitamin D status is associated with epithelial-mesenchymal transition in patients with chronic obstructive pulmonary disease. J Immunol. 2019;203(6):1428–1435. doi:10.4049/jimmunol.1900229
   PubMed Web of Science ®Google Scholar
• Fu L, Fei J, Tan ZX, et al. Low vitamin D status is associated with inflammation in patients with chronic obstructive pulmonary disease. J Immunol. 2021;206(3):515–523. doi:10.4049/jimmunol.2000964
   PubMed Web of Science ®Google Scholar
• Arsalane K, Broeckaert F, Knoops B, Wiedig M, Toubeau G, Bernard A. Clara cell specific protein (CC16) expression after acute lung inflammation induced by intratracheal lipopolysaccharide administration. Am J Respir Crit Care Med. 2000;161(5):1624–1630. doi:10.1164/ajrccm.161.5.9812157
   PubMed Web of Science ®Google Scholar
• Sarkar K, Dhatrak S, Sarkar B, Ojha UC, Raghav P, Pagdhune A. Secondary prevention of silicosis and silico-tuberculosis by periodic screening of silica dust exposed workers using serum club cell protein 16 as a proxy marker. Health Sci Rep. 2021;4(3):e373. doi:10.1002/hsr2.373
   PubMedGoogle Scholar
• Fu L, Li XY, Fei J, et al. Myocardial injury at early stage and its association with the risk of death in COVID-19 patients: a hospital-based retrospective cohort study. Front Cardiovasc Med. 2020;7:590688. doi:10.3389/fcvm.2020.590688
   PubMed Web of Science ®Google Scholar
• Fu L, Fei J, Xu S, et al. Liver dysfunction and its association with the risk of death in COVID-19 patients: a prospective cohort study. J Clin Transl Hepatol. 2020;8(3):246–254. doi:10.14218/JCTH.2020.00043
   PubMed Web of Science ®Google Scholar
• Xiang HX, Fei J, Xiang Y, et al. Renal dysfunction and prognosis of COVID-19 patients: a hospital-based retrospective cohort study. BMC Infect Dis. 2021;21(1):158. doi:10.1186/s12879-021-05861-x
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao Y, Pan L, He X, Zhang X. The relationship between the expression of serum IL-18 mRNA, CC16, and sTREM-1 and the severity and prognosis of ventilator-associated pneumonia in elderly patients. Ann Palliat Med. 2021;10(12):12767–12774. doi:10.21037/apm-21-3511
   PubMed Web of Science ®Google Scholar
• Guerra S, Vasquez MM, Spangenberg A, Halonen M, Martinez FD. Serum concentrations of club cell secretory protein (Clara) and cancer mortality in adults: a population-based, prospective cohort study. Lancet Respir Med. 2013;1(10):779–785. doi:10.1016/S2213-2600(13)70220-0
   PubMed Web of Science ®Google Scholar
• Halatek T, Sinczuk-Walczak H, Rydzynski K. Prognostic significance of low serum levels of Clara cell phospholipid-binding protein in occupational aluminium neurotoxicity. J Inorg Biochem. 2005;99(9):1904–1911. doi:10.1016/j.jinorgbio.2005.06.027
   PubMed Web of Science ®Google Scholar
• Johnson MDL, Younis US, Menghani SV, et al. CC16 binding to α4β1 integrin protects against mycoplasma pneumoniae infection. Am J Respir Crit Care Med. 2021;203(11):1410–1418. doi:10.1164/rccm.202006-2576OC
   PubMed Web of Science ®Google Scholar
• Park HY, Churg A, Wright JL, et al. Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(12):1413–1419. doi:10.1164/rccm.201305-0892OC
   PubMed Web of Science ®Google Scholar
• Guerra S, Halonen M, Vasquez MM, et al. Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study. Lancet Respir Med. 2015;3(8):613–620. doi:10.1016/S2213-2600(15)00196-4
   PubMed Web of Science ®Google Scholar
• Hsu HS, Liu CC, Lin JH, Hsu TW, Su K, Hung SC. Repair of naphthalene-induced acute tracheal injury by basal cells depends on β-catenin. J Thorac Cardiovasc Surg. 2014;148(1):322–332. doi:10.1016/j.jtcvs.2013.10.039
   PubMed Web of Science ®Google Scholar
• Sarker RSJ, Conlon TM, Morrone C, et al. CARM1 regulates senescence during airway epithelial cell injury in COPD pathogenesis. Am J Physiol Lung Cell Mol Physiol. 2019;317(5):L602–L614. doi:10.1152/ajplung.00441.2018
   PubMed Web of Science ®Google Scholar
• Yin W, Cao W, Zhou G, et al. Analysis of pathological changes in the epithelium in COVID-19 patient airways. ERJ Open Res. 2021;7(2):00690–02020. doi:10.1183/23120541.00690-2020
   PubMedGoogle Scholar
• Almuntashiri S, James C, Wang X, Siddiqui B, Zhang D. The potential of lung epithelium specific proteins as biomarkers for COVID-19-associated lung injury. Diagnostics. 2021;11(9):1643. doi:10.3390/diagnostics11091643
   Web of Science ®Google Scholar
• Almuntashiri S, Han Y, Zhu Y, et al. CC16 regulates inflammation, ROS generation and apoptosis in bronchial epithelial cells during Klebsiella pneumoniae infection. Int J Mol Sci. 2021;22(21):11459. doi:10.3390/ijms222111459
   PubMed Web of Science ®Google Scholar
• Lee J, Komatsu K, Lee BC, et al. Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by Streptococcus pneumoniae by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway. J Biol Chem. 2012;287(27):22799–22811. doi:10.1074/jbc.M111.337378
   PubMed Web of Science ®Google Scholar